There are 2137 resources available
LBA73 - The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01
Presenter: Pia Kvistborg
Session: Proffered Paper - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA74 - Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)
Presenter: Deborah Doroshow
Session: Proffered Paper - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA75 - Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)
Presenter: Javier Baena Espinar
Session: Proffered Paper - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
1619O - High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
CN6 - Health literacy in informal carers in relation to breast cancer prevention: A qualitative research in three European countries
Presenter: Tsitsi Theologia
Session: EONS13: Supporting informal carers
Resources:
Abstract
Slides
Webcast
524O - Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours
Presenter: Lillian Siu
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
525O - A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
Presenter: Geoffrey Ku
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
526O - High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
Presenter: Benoit Rousseau
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
527O - CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study
Presenter: Victor Moreno Garcia
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
528O - CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
Presenter: Antoine Hollebecque
Session: Proffered Paper - Developmental therapeutics
Resources:
Abstract
Slides
Webcast